Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
about
Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.Primary bone natural killer/T cell lymphoma, nasal type without EBV infection: a case report.S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabineConsolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphomaEfficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphomaUtility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase.The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.CD56- extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white manA phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma.Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature.Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
P2860
Q33418045-B59674CE-3362-4FE8-BE3A-69BC476F7D81Q33423016-8BA2F043-D646-4D49-94E6-00DBC63CDD2FQ33429990-E80AEA20-6105-4040-AADD-71D201085611Q33433689-800D3A95-1F07-4A17-99D7-5F2B589F286DQ36464664-8082CBDD-837D-4BEC-961A-E4884DD5CDF1Q36735918-A1F4CBAF-3612-4FB3-B539-A804D9A14330Q36760583-3324D19F-F4FA-4EC3-99D1-11CEE847DB1FQ37301747-A81F7CA7-B0BA-4B59-B309-25E16D2FADD0Q37376566-24D863D2-D565-457D-B79E-6B5A14960761Q37602246-5120E41C-2E34-4EC3-A912-42343C5F1A12Q37629033-4237EC60-F8F9-4C4D-88A0-F2B20888BA19Q37706931-5696A72F-03EB-45EE-9F7A-32BF3DCE9806Q38835470-C4A5D23A-8826-4657-BE27-517EBCC87B14Q40040761-536ADC62-9A05-4318-9A61-D9A01EA8F4A7Q40103866-6B952D4A-E9F2-4D69-9E2C-333AE2EAF6A4Q40441775-5E115DEE-ADA2-4114-8BFD-6ECF3C69BCBCQ40535907-641E6AE8-D8F1-43D4-8675-AE535B27C2B2Q49730092-60027274-378B-43AA-A623-C537F461653CQ50895128-E81EAA42-A917-41B1-A3FF-4BB6857A267CQ54221393-43329AD5-6A6F-4B3F-B096-B86A82E482CDQ59126103-DB812BDE-4DDE-42DD-B7B8-826FF58536D6
P2860
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@ast
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@en
type
label
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@ast
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@en
prefLabel
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@ast
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@en
P2093
P2860
P1433
P1476
Effectiveness of gemcitabine, ...... spective study of 17 patients.
@en
P2093
Beibei Qin
Changying Chen
Jianguo Wen
Jiaqin Yan
Jingjing Wu
Mingzhi Zhang
P2860
P304
P356
10.1007/S00277-014-2136-7
P50
P577
2014-06-13T00:00:00Z